Published on in Vol 2, No 3 (2021): Jul-Sep

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/28255, first published .
Impact of Modifiable Risk Factors on the Occurrence of Cutaneous Leishmaniasis in Diyala, Iraq: Case-Control Study

Impact of Modifiable Risk Factors on the Occurrence of Cutaneous Leishmaniasis in Diyala, Iraq: Case-Control Study

Impact of Modifiable Risk Factors on the Occurrence of Cutaneous Leishmaniasis in Diyala, Iraq: Case-Control Study

Journals

  1. Al-Dubaiee R. Peer Review of “Impact of Modifiable Risk Factors on the Occurrence of Cutaneous Leishmaniasis in Diyala, Iraq: Case-Control Study”. JMIRx Med 2021;2(3):e31513 View
  2. Taher R. Peer Review of “Impact of Modifiable Risk Factors on the Occurrence of Cutaneous Leishmaniasis in Diyala, Iraq: Case-Control Study”. JMIRx Med 2021;2(3):e31514 View
  3. Nassar A. Peer Review of “Impact of Modifiable Risk Factors on the Occurrence of Cutaneous Leishmaniasis in Diyala, Iraq: Case-Control Study”. JMIRx Med 2021;2(3):e31515 View
  4. Lehlewa A, Khaleel H, Lami F, Hasan S, Malick H, Mohammed R, Abdulmottaleb Q. Authors’ Response to Peer Reviews of “Impact of Modifiable Risk Factors on the Occurrence of Cutaneous Leishmaniasis in Diyala, Iraq: Case-Control Study”. JMIRx Med 2021;2(3):e31512 View
  5. Knight C, Harris D, Alshammari S, Gugssa A, Young T, Lee C. Leishmaniasis: Recent epidemiological studies in the Middle East. Frontiers in Microbiology 2023;13 View
  6. Muhammed Hassan G, Ali H, Muhammed Hussein W. Evaluation of IL-8, nitric oxide and macrophage inhibitory factor as clinical circulatory markers in patients with cutaneous leishmaniasis, before and during sodium stibogluconate treatment. Cytokine 2024;173:156450 View